J. Nowakowska1, D. R. Cameron1, A. De Martino2, J. Kühn1, S. Le Fresne-Languille2, S. Leuillet2, Y. Amouzou2,
F. Wittke3, T. Carton2, F. Le Vacon2, R. L. Chaves3, V. Nicolas-Metral1 and G. Vuagniaux1
1 Translational Medicine Department, Debiopharm International SA, Chemin Messidor 5-7, 1006 Lausanne, Switzerland
2Research and Development Department, Biofortis SAS, 3 route de la Chatterie, 44800 Saint-Herblain, France
3Clinical Development Department, Debiopharm International SA, Chemin Messidor 5-7, 1006 Lausanne, Switzerland
Antibiotic use is associated with collateral damage to the healthy microbiota. Afabicin is a first-in-class prodrug inhibitor of the FabI enzyme that, when converted to the pharmacologically active agent afabicin desphosphono, demonstrates a staphylococcal-specific spectrum of activity. An expected benefit of highly targeted antibiotics such as afabicin is microbiome preservation.
To compare the effects of oral treatment with afabicin and standard-of-care antibiotics upon the murine gut microbiota, and to assess the effects of oral afabicin treatment on the human gut microbiota.